Browse our 650+ Publications​

Latest Publications

BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma

Kremenovic M, et al.
Journal for ImmunoTherapy of Cancer
August 2022
Authors and Affiliates
Mirela Kremenovic 1,2, Alfred A Chan 3, Bing Feng 4, Lukas Bäriswyl 1, Steve Robatel 1,2, Thomas Gruber 1, Li Tang 4, Delphine J Lee 3, Mirjam Schenk 5; 1 Experimental Pathology, University of Bern Institute of Pathology, Bern, Switzerland. 2 Graduate School Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland. 3 Division of Dermatology, Department of Medicine, The Lundquist Institute, Torrance, California, USA. 4 Institute of Bioengineering and Institute of Materials Science and Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, VD, Switzerland. 5 Experimental Pathology, University of Bern Institute of Pathology, Bern, Switzerland mirjam.schenk@pathology.unibe.ch.

High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments

Fernandez N, et al.
August 2022
Authors and Affiliates
Nicolas Fernandez 1, Deepak Perumal 2, Adeeb Rahman 3, Seunghee Kim-Schulze 3, Jen Yesil 4, Daniel Auclair 4, Homer Adams 3rd 5, Samir Parekh 6, Sacha Gnjatic 7, Hearn Jay Cho 8; 1 Precision Immunology Institute. 2 Tisch Cancer Institute. 3 Human Immune Monitoring Center. 4 Multiple Myeloma Research Foundation, Norwalk, CT. 5 Janssen Research & Development, LLC, Spring House, PA. 6 Precision Immunology Institute; Tisch Cancer Institute; Department of Oncological Sciences, Icahn School of Medicine at Mt. Sinai, New York, NY. 7 Precision Immunology Institute; Tisch Cancer Institute; Human Immune Monitoring Center. 8 Precision Immunology Institute; Tisch Cancer Institute; Multiple Myeloma Research Foundation, Norwalk, CT. Electronic address: hearn.jay.cho@mssm.edu.

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma.

Martin T, et al.
Blood Advances
August 2022
Authors and Affiliates
Thomas Martin,1 Joseph Mikhael,2 Roman Hajek,3 Kihyun Kim,4 Kenshi Suzuki,5 Cyrille Hulin,6 Mamta Garg,7 Hang Quach,8 Hanlon Sia,9 Anup George,10 Tatiana Konstantinova,11 Marie-Laure Risse,12 Gaelle Asset,13 Sandrine Macé,12 Helgi van de Velde,14 and Philippe Moreau15 1Department of Medicine, University of California, San Francisco, CA; 2Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ; 3Department of Hemato-Oncology, University Hospital Ostrava, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic; 4Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.; 5Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan; 6Department of Hematology, University Hospital Bordeaux, Bordeaux, France; 7Department of Haematology, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, UK; 8Department of Haematology, St Vincent's Hospital, University of Melbourne, Vic, Australia; 9Cancer Care & Haematology Unit, The Tweed Hospital, Tweed Heads, NSW, Australia; 10Wellington Blood and Cancer Center, Wellington, New Zealand; 11Hematology Department, Regional Hospital #1, Ekaterinburg, Russia; 12Sanofi Research and Development, Vitry-Sur-Seine, France; 13Sanofi Research and Development, Chilly-Mazarin, France; 14Sanofi, Cambridge, MA; 15Department of Hematology, University Hospital of Nantes, Nantes, France

Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation.

Taranto E, et al.
August 2022
Authors and Affiliates
Eleanor Tarantoa, Robert Reddb, Erin Jeterc, Kristin McHughc, Jennifer L. Crombiec, David C. Fisherc,Eric Jacobsenc, Caron A. Jacobsonc, Austin I. Kimc, Ann S. LaCascec, Oreofe O. Odejidec, Parastoo B. Dahid,Yago Nietoe, Robin M. Joycef, Yi-Bin Cheng, Kimberley-Jane C. Bonjoch, Ammar Chaudhryh,Alex F. Herrerah, Philippe Armandc and Reid W. Merrymanc aDepartment of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; bDepartment of Data Sciences, Dana-Farber CancerInstitute, Boston, MA, USA; cDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA; d Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; eDepartment of StemCell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; fDepartment of Hematologic Malignancy, Beth Israel Deaconess Medical Center, Boston, MA, USA; gHematopoietic Cell Therapy and Transplant Program, Massachusetts General Hospital, Boston, MA, USA; hDepartment of Hematology and Hematopoietic Cell Transplantation,City of Hope National Medical Center, Duarte, CA, USA

Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy.

Bal S, et al.
American Journal of Hematology
July 2022
Authors and Affiliates
Susan Bal, MD1,2, Binod Dhakal, MD3, Rebecca W. Silbermann, MD4,Timothy M. Schmidt, MD5, Bhagirathbhai Dholaria, MD6, Smith Giri, MD1,2,Saurabh Chhabra, MD3, Eva Medvedova, MD4, Kelly N. Godby, MD1,2, Anita D'Souza, MD3, Aric C. Hall, MD5, Pamela Hardwick, RN1,2, Jim Omel, MD7, Robert F. Cornell, MD6, Parameswaran Hari, MD3, Natalie S. Callander, MD5, and Luciano J. Costa, MD, PhD1,2 1Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL 2O’Neal Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, AL 3Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 4Oregon Health & Science University, Portland, OR 5University of Wisconsin, Madison, WI 6Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN 7Independent Patient Advocate, Omaha, NE

Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.

Derman BA, et al.
JAMA Oncology
July 2022
Authors and Affiliates
Benjamin A. Derman, MD; Ankit Kansagra, MD; Jeffrey Zonder, MD; Andrew T. Stefka, BS; David L. Grinblatt, MD; Larry D. Anderson Jr, MD, PhD; Sandeep Gurbuxani, MD, PhD; Sunil Narula, MD; Shayan Rayani, MD;Ajay Major, MD; Andrew Kin, MD; Ken Jiang, BS; Theodore Karrison, PhD; Jagoda Jasielec, MD; Andrzej J. Jakubowiak, MD, PhD University of Chicago Medical Center, Chicago, Illinois (Derman, Stefka, Gurbuxani, Narula, Rayani, Major, Jiang, Karrison, Jasielec, Jakubowiak); Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas (Kansagra, Anderson); Karmanos Cancer Institute, Wayne State University, Detroit, Michigan (Zonder, Kin); NorthShore University Health Systems, Evanston, Illinois (Grinblatt).

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse.

Short NJ, et al.
Blood Advances
July 2022
Authors and Affiliates
Nicholas J. Short,1 Hagop Kantarjian,1 Farhad Ravandi,1 Marina Konopleva,1 Nitin Jain,1 Rashmi Kanagal-Shamanna,2 Keyur P. Patel,2 Walid Macaron,1 Tapan M. Kadia,1 Sa Wang,2 Jeffrey L. Jorgensen,2 Joseph D. Khoury,2 Musa Yilmaz,1 Partow Kebriaei,3 Koichi Takahashi,1 Guillermo Garcia-Manero,1 Naval Daver,1 Sean M. Post,1 Xuelin Huang,4 Steven M. Kornblau,1 Sara Pelletier,1 Wilmer Flores,1 Jairo Matthews,1 Rebecca Garris,1 and Elias Jabbour1 1Department of Leukemia, 2Department of Hematopathology, 3Department of Stem Cell Transplantation & Cellular Therapy, and 4Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.

Richardson PG, et al.
New England Journal of Medicine
June 2022
Authors and Affiliates
P.G. Richardson, S.J. Jacobus, E.A. Weller, H. Hassoun, S. Lonial, N.S. Raje, E. Medvedova, P.L. McCarthy, E.N. Libby, P.M. Voorhees, R.Z. Orlowski, L.D. Anderson, Jr., J.A. Zonder, C.P. Milner, C. Gasparetto, M.E. Agha, A.M. Khan, D.D. Hurd, K. Gowin, R.T. Kamble, S. Jagannath, N. Nathwani, M. Alsina, R.F. Cornell, H. Hashmi, E.L. Campagnaro, A.C. Andreescu, T. Gentile, M. Liedtke, K.N. Godby, A.D. Cohen, T.H. Openshaw, M.C. Pasquini, S.A. Giralt, J.L. Kaufman, A.J. Yee, E. Scott, P. Torka, A. Foley, M. Fulciniti, K. Hebert, M.K. Samur, K. Masone, M.E. Maglio, A.A. Zeytoonjian, O. Nadeem, R.L. Schlossman, J.P. Laubach, C. Paba-Prada, I.M. Ghobrial, A. Perrot, P. Moreau, H. Avet-Loiseau, M. Attal, K.C. Anderson, and N.C. Munshi, for the DETERMINATION Investigators The Department of Medical Oncology, Dana–Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana–Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children’s Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport–Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) — all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) — all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology–Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) — all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom’s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) — all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) — both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) — both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) — both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O’Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology andOncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse–Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) — both in France.

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.

Martin T, et al.
Journal of Clinical Oncology
June 2022
Authors and Affiliates
Thomas Martin, MD1; Saad Z. Usmani, MD2; Jesus G. Berdeja, MD3; Mounzer Agha, MD4; Adam D. Cohen, MD5; Parameswaran Hari, MD6;David Avigan, MD7; Abhinav Deol, MD8; Myo Htut, MD9; Alexander Lesokhin, MD2; Nikhil C. Munshi, MD10,11; Elizabeth O’Donnell, MD12; A. Keith Stewart, MBChB13; Jordan M. Schecter, MD14; Jenna D. Goldberg, MD14; Carolyn C. Jackson, MD, MPH14; Tzu-Min Yeh, MS14; Arnob Banerjee, MD15; Alicia Allred, PhD15; Enrique Zudaire, PhD15; William Deraedt, MSc16; Yunsi Olyslager, MSc16; Changwei Zhou, PhD17; Lida Pacaud, MD17; Deepu Madduri, MD14; Andrzej Jakubowiak, MD18; Yi Lin, MD, PhD19; and Sundar Jagannath, MD20 1UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 2Memorial Sloan Kettering Cancer Center, New York, NY 3Sarah Cannon Research Institute, Nashville, TN 4UPMC Hillman Cancer Center, Pittsburgh, PA 5Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 6Medical College of Wisconsin, Milwaukee, WI 7Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 8Karmanos Cancer Institute, Wayne State University, Detroit, MI 9 City of Hope Comprehensive Cancer Center, Duarte, CA 10Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 11VA Boston Healthcare System, West Roxbury, MA 12Massachusetts General Hospital, Harvard Medical School, Boston, MA 13University Health Network and the Princess Margaret Cancer Centre, Toronto, ON, Canada 14Janssen R&D, Raritan, NJ 15Janssen R&D, Spring House, PA 16Janssen R&D, Beerse, Belgium 17Legend Biotech, Inc, Piscataway, NJ 18University of Chicago, Chicago, IL 19Mayo Clinic, Rochester, MN 20Mount Sinai Medical Center, New York, NY

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.

Wang M, et al.
Journal of Clinical Oncology
June 2022
Authors and Affiliates
Michael Wang, MD1; Javier Munoz, MD, MS, MBA2; Andre Goy, MD, MS3; Frederick L. Locke, MD4; Caron A. Jacobson, MD, MMSc5;Brian T. Hill, MD, PhD6; John M. Timmerman, MD7; Houston Holmes, MD, MBA8; Samantha Jaglowski, MD9; Ian W. Flinn, MD, PhD10;Peter A. McSweeney, MB, ChB11; David B. Miklos, MD, PhD12; John M. Pagel, MD, PhD, DSc13; Marie Jose Kersten, MD, PhD ´ 14;Krimo Bouabdallah, MD15; Rashmi Khanal, MD16; Max S. Topp, MD17; Roch Houot, MD, PhD18; Amer Beitinjaneh, MD19;Weimin Peng, PhD20; Xiang Fang, PhD20; Rhine R. Shen, PhD20; Rubina Siddiqi, PhD20; Ioana Kloos, MD20; and Patrick M. Reagan, MD21 1The University of Texas MD Anderson Cancer Center, Houston, TX 2Banner MD Anderson Cancer Center, Gilbert, AZ 3John Theurer Cancer Center, Hackensack University, Hackensack, NJ 4Moffitt Cancer Center, Tampa, FL 5Dana-Farber Cancer Institute, Boston, MA 6Cleveland Clinic Foundation, Cleveland, OH 7David Geffen School of Medicine at UCLA, Los Angeles, CA 8Texas Oncology, Dallas, TX 9The Ohio State University Comprehensive Cancer Center, Columbus, OH 10Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN 11Colorado Blood Cancer Institute, Denver, CO 12Stanford University School of Medicine, Stanford, CA 13Swedish Cancer Institute, Seattle, WA 14Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, the Netherlands, on behalf of HOVON/LLPC 15CHU Bordeaux, Service d’Hematologie et th ´ erapie Cellulaire, ´Bordeaux, France 16Fox Chase Cancer Center, Philadelphia, PA 17Medizinische Klinik und Poliklinik II, Universitatsklinikum W ¨ urzburg, ¨Wurzburg, Germany ¨ 18CHU Rennes, Universite Rennes, INSERM & EFS, Rennes, France ´ 19University of Miami, Miami, FL 20Kite, a Gilead Company, Santa Monica, CA 21University of Rochester Medical Center, Rochester, NY